A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
Recruiting · NCT06758544 · Interventional (participants receive a specific treatment) · Lead sponsor: Guangdong Provincial People's Hospital
View the official record on ClinicalTrials.gov →Interventions studied
ChemotherapyOncolytic virus VRT106
What this trial is about
This is a single-center, single-arm, open investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of resectable pancreatic cancer.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1, Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Subject voluntarily agrees to participate in this study and signs an Institutional Review Board -approved informed consent prior to performing any of the Screening Visit procedures.
- Males and females at 18-75 years of age, inclusive, at the Screening Visit.
- Have a clinical diagnosis of pancreatic cancer.
- An Eastern Cooperative Oncology Group (ECOG) score of 0 or 1.
- Expected survival time of≥6 months.
- No serious hematologic and cardiac abnormalities of the liver, kidneys, or coagulation functions.
Exclusion criteria
- Prior treatment with other oncolytic virus or systemic therapy for pancreatic cancer.
- Previous allogeneic hematopoietic stem cell transplantation or organ transplantation.
- Immunocompromised patients.
- Known alcohol or drug dependency.
- Women who are pregnant or breastfeeding.
Where it is running
1 location listed.
- Guangdong Provincial People's Hospital - Guangzhou, Guangdong, China